A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer
A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer
复制标题
DOI：
10.1016/j.canlet.2013.09.011
复制
发表时间：
2014-02-01
期刊：
影响因子：
9.7
通讯作者：
Tredan, Olivier
中科院分区：
文献类型：
--
作者：
Jobard, Elodie;Pontoizeau, Clement;Tredan, Olivier
乳腺癌（BC）从组织学到预后、转移演变和治疗反应都表现出高度异质性。我们在这里报告了一项基于H-1 NMR的代谢表型研究，旨在确定与晚期转移性乳腺癌（MBC）相关的协调代谢血清变化，与局部早期疾病（EBC）相比。获得区分EBC和MBC患者的模型（n = 85：46 EBC和39 MBC），并用独立队列验证（n = 112：61 EBC和51 MBC; 89.8%灵敏度，79.3%特异性）。我们确定了9个统计学显著的代谢产物参与这种歧视：组氨酸，乙酰乙酸，甘油，丙酮酸，糖蛋白（N-乙酰基），甘露糖，谷氨酸和苯丙氨酸。这项工作说明了核磁共振代谢表型的诊断，预后和癌症患者的管理的强大潜力。(C)2013爱思唯尔爱尔兰有限公司版权所有。
Breast cancer (BC) displays a high heterogeneity from histology to prognosis, metastatic evolution and treatment responses. We report here a H-1 NMR-based metabolic phenotyping study aiming at identifying coordinated metabolic serum changes associated with advanced metastatic breast cancer (MBC) in comparison to the localized early disease (EBC). A model discriminating EBC and MBC patients is obtained (n = 85: 46 EBC and 39 MBC), and validated with an independent cohort (n = 112: 61 EBC and 51 MBC; 89.8% sensitivity, 79.3% specificity). We identify 9 statistically significant metabolites involved in this discrimination: histidine, acetoacetate, glycerol, pyruvate, glycoproteins (N-acetyl), mannose, glutamate and phenylalanine. This work illustrates the strong potential of NMR metabolic phenotyping for the diagnosis, prognosis, and management of cancer patients. (C) 2013 Elsevier Ireland Ltd. All rights reserved.